Slow channel congenital myasthenic syndrome responsive to a combination of fluoxetine and salbutamol

Muscle and Nerve

Volumn 47, Issue 2, 2013, Pages 279-282

  Finlayson, Sarah ^a   Spillane, Jennifer ^b,c   Kullmann, Dimitri M ^b,c   Howard, Robin ^c   Webster, Richard ^a   Palace, Jacqueline ^a   Beeson, David ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

Acetylcholine receptor; CHRNE mutations; Fluoxetine; Salbutamol; Slow channel congenital myasthenic syndrome therapy

Indexed keywords

FLUOXETINE; NEOSTIGMINE; SALBUTAMOL;

ADD ON THERAPY; ADULT; ARTICLE; ASSISTED VENTILATION; CELL STRAIN HEK293; CONGENITAL MYASTHENIC SYNDROME; CONTROLLED STUDY; DISEASE COURSE; ELECTROPHYSIOLOGY; GENE EXPRESSION; GENE MUTATION; GENETIC ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MOLECULAR GENETICS; MUSCULAR DYSTROPHY; PRIORITY JOURNAL; PROGENY; PTOSIS; RESPIRATORY FAILURE; TRACHEOSTOMY; TREATMENT RESPONSE; WILD TYPE;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; ALBUTEROL; DRUG THERAPY, COMBINATION; FLUOXETINE; HUMANS; MALE; MIDDLE AGED; MUTATION; MYASTHENIC SYNDROMES, CONGENITAL; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 84873042855     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.23534     Document Type: Article

References (14)

1. Engel AG. Current status of the congenital myasthenic syndromes. Neuromuscul Disord 2012; 22: 478.
2. Beeson D, Hantaï D, Lochmüller H, Engel AG. 126th International Workshop: Congenital Myasthenic Syndromes, 24-26 September 2004, Naarden, The Netherlands. Neuromuscul Disord 2005; 15: 498-512.
3. Palace J, Beeson D. The congenital myasthenic syndromes. J Neuroimmunol 2008; 201-202:2-5.
4. Engel AG. The therapy of congenital myasthenic syndromes. Neurotherapeutics 2007; 4: 252-257.
5. Croxen R, Hatton C, Shelley C, Brydson M, Chauplannaz G, Oosterhuis H, et al. Recessive inheritance and variable penetrance of slow-channel congenital myasthenic syndromes. Neurology 2002; 59: 162-168.
6. Croxen R, Hatton C, Shelley C, Brydson M, Chauplannaz G, Oosterhuis H, et al. Voluntary partial retraction of: recessive inheritance and variable penetrance of slow-channel congenital myasthenic syndromes. Neurology 2009; 72: 294.
7. Shelley C, Colquhoun D. A human congenital myasthenia-causing mutation (epsilon L78P) of the muscle nicotinic acetylcholine receptor with unusual single channel properties. J Physiol Lond 2005; 564: 377-396 [corrigendum J Physiol 2009; 586: 5277].
8. Sarrigiannis PG, Kennett RP, Read S, Farrugia ME. Single-fiber EMG with a concentric needle electrode: validation in myasthenia gravis. Muscle Nerve 2006; 33: 61-65.
9. Jaretzki A, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS, et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 2000; 55: 16-23.
10. Webster RG, Lashley D, Cossins J, Maxwell S, Beeson D. Ephedrine ameliorates impaired neuromuscular transmission in an animal model of the slow channel congenital myasthenic syndrome. Program No. 590.8. 2010 Neuroscience Meeting Planner. San Diego, CA: Society for Neuroscience; 2010 [online].
11. Lee WY, Free CR, Sine SM. Binding to gating transduction in nicotinic receptors: Cys-loop energetically couples to pre-M1 and M2-M3 regions. J Neurosci 2009; 29: 3189-199.
12. Lashley D, Palace J, Jayawant S, Robb S, Beeson D. Ephedrine treatment in congenital myasthenic syndrome due to mutations in DOK7. Neurology 2010; 74: 1517-1523.
13. Liewluck T, Selcen D, Engel AG. Beneficial effects of albuterol in congenital endplate acetylcholinesterase deficiency and Dok-7 myasthenia. Muscle Nerve 2011; 44: 789-794.
14. Sadeh M, Shen X-M, Engel AG. Beneficial effect of albuterol in congenital myasthenic syndrome with epsilon subunit mutations. Muscle Nerve 2011; 44: 289-291.